Skip to main content

4 Result(s)

within I. Ieiri Remove this filter

and

  1. No Access

    Article

    Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

    Background: Little is known about differences in the disposition kinetics and pharmacological effects on gastrin levels between lansoprazole and rabeprazole given in a repeated dosing scheme with respect to the ...

    I. Ieiri, Y. Kishimoto, H. Okochi, K. Momiyama… in European Journal of Clinical Pharmacology (2001)

  2. No Access

    Article

    Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9 * 3 allele

    Objectives: Evidence exists to suggest that diclofenac is metabolised by CYP2C9. The present study was undertaken in order to evaluate the effect of the single CYP2C9*3 variant on drug m...

    J. Shimamoto, I. Ieiri, A. Urae, M. Kimura… in European Journal of Clinical Pharmacology (2000)

  3. No Access

    Article

    CYP2C19 polymorphism effect on phenobarbitone

    Objective: The aim of this study was to clarify the effect of genetic polymorphisms of CYP2C19 on the pharmacokinetics of phenobarbitone (PB) using a nonlinear mixed-effects model (NONMEM) analysis in Japanese a...

    K. Mamiya, A. Hadama, E. Yukawa, I. Ieiri… in European Journal of Clinical Pharmacology (2000)

  4. No Access

    Article

    Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic-gingival hyperplasia: in vivo and in vitro study

    The purpose of this study was to assess the possible role of the (R)- and (S)- enantiomers of the phenytoin metabolite p-HPPH in the pathogenesis of gingival hyperplasia (GH). About 98% of circulating p-HPPH i...

    I. Ieiri, W. Goto, S. Higuchi, K. Hirata… in European Journal of Clinical Pharmacology (1995)